Aoife Brennan, M.B., Ch.B.

Aoife brings to Climb Bio over 20 years of experience leading drug development organizations across a range of stages and therapeutic areas having most recently served as the President and Chief Executive Officer of Synlogic, a clinical stage biotechnology company developing treatments for rare metabolic diseases based on synthetic biology.  She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018. Prior to Synlogic, Aoife served as Vice President and Head of the Rare Disease Innovation Unit at Biogen, Inc., where she led the global marketing approvals of ALPROLIX®, ELOCTATE® and SPINRAZA® as well as other early-stage programs. She has served as a director and advisor to several public and private biotech companies including Ra Pharmaceuticals, Inc. (acquired by UCB), and is currently a member of the BOD of Fibrogen Inc., Cerevance, LLC and Xilio Therapeutics.

Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. She is fellowship trained in internal medicine, endocrinology and metabolism.